Molecules and methods for brain targeting pharmaceuticals
| Reference number | |
| Coordinator | Key2Brain AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | June 2020 - October 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2020 |
Important results from the project
The current project aims at developing unique brain targeting molecules for more effective treatment of brain diseases with biological drugs. Most neurodegenerative diseases today lack effective treatments. Promising biological drugs currently under development have an inherent difficulty in reaching their target in the brain, due to the protective blood-brain barrier. During the course of the project, our platform technology aimed at developing brain targeting molecules has been tested and validated and the project is now ready for the next step.
Expected long term effects
Promising results have emerged from our methodological and technological development. We are optimistic for future developments which could entail more efficient therapeutics and new diagnostic tools for brain disease.
Approach and implementation
During the project, we have focused on the development of methods and prototypes, and validation of these. The project has been affected by external factors, and deviated slightly from the original plan. The project has also seen effects of Covid-19 which has delayed certain activities,